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JOHN THOMAS LUKISH 
ABSTRACT 
There is clear evidence that obesity and asthma are among today’s most prevalent, 
threatening, and burdensome childhood afflictions. Research strongly suggests that these 
two disorders, when occurring concurrently, are in fact, a distinct disease state. There 
exists two prominent asthma phenotypes, both of which are related in different degrees 
with obesity. These are early-onset, atopic and late-onset, non-atopic obesity-related 
asthma. The linkage between obesity and asthma is complex as both disorders cause a 
variety of metabolic and immunological changes that can affect different, yet 
interconnecting compartments and functions of the body. The main objective of this 
review is to summarize the principal findings that pathologically link obesity and asthma 
and the pharmacologic and non-pharmacologic therapies that are currently in use to 
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Asthma is one of the most clinically significant pediatric respiratory diseases in the 
United States. The Global Strategy for Asthma Management and Prevention, written and 
compiled by the Global Initiative for Asthma, defines asthma as a heterogeneous disease 
characterized by chronic airway inflammation and a history of specific respiratory 
symptoms (Reddel et al., 2015). In children, these symptoms typically are cough, 
wheezing, chest tightness, prolonged exhalation, and/or shortness of breath. Among 
these, cough and wheezing, particularly in recurrent episodes, are the most prominent 
effects of asthma, although the absence of these symptoms cannot exclude the disease 
(National Asthma Education and Prevention Program, 2007). Children, especially those 
less than 1 year of age, who present with isolated chronic cough in the absence of 
wheeze, sudden onset of symptoms with no obvious trigger, absence of nocturnal cough, 
poor or no response to standard asthma management are unlikely to have asthma (Reddel 
et al., 2015). Importantly, these presentations can change in intensity or be completely 
absent based on environmental and physiological factors such as season, presence of 
respiratory infections, allergens, stress, and emotional state (National Asthma Education 
and Prevention Program, 2007). 
 
Among the 26.5 million afflicted with the disorder in 2016, nearly 6 million were 
children of the age 18 years or younger (Centers for Disease Control and Prevention, 
2018). In children, asthma is more prevalent in males (9.2%) then females (7.4%), and is 
more common in non-Hispanic blacks (11.5%) compared to non-Hispanic whites (8.3%) 
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and Hispanics (6.6%). There were 14 newly diagnosed cases of asthma made per 1000 
children per year in these at risk populations between 2006 and 2008, and among this 
group, the incidence rate was the highest in children age 0-5, which was nearly 24 per 
1000 children per year (Winer et al., 2012). The total direct cost of pediatric asthma, 
which includes diagnostics, outpatient and emergency visits, medications, and 
hospitalizations, in 2013 was $6.31 billion in 2018 dollars adjusted for inflation (Sullivan 
et al., 2017). Risk factors for the disease in children include epigenetic and genetic-
related aberrations, increased environmental exposure particularly to pollutants in urban 
areas, decreased microbial exposure early in life, and a family history of atopy (Ferrante 
et al., 2018, Toskala et al., 2015). A diagnosis of asthma is clinically made utilizing the 
patient’s medical and family history, physical examination, spirometry, exhaled fractional 
nitric oxide, and challenge testing. However, with preschool-aged children, who are 
unable to be tested via spirometry and challenge testing, a diagnosis relies on the details 
surrounding exacerbation episodes of common symptoms, taking care to note duration, 
severity, and time of day.  
 
The goal of asthma therapy is to maintain control on the least amount of medication. 
Control is defined in terms of reducing the risk of exacerbations and minimizing 
impairment due to everyday symptoms (National Asthma Education and Prevention 
Program, 2007). For daily, mild exacerbations, pediatric asthmatic patients utilize a 
reliever, usually a short-acting beta-2 agonist (SABA), commonly in the form of albuterol 
or levalbuterol (Reddel et al., 2015). Patients that experience uncontrolled symptoms who 
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may be diagnosed as having severe asthma typically use combination therapy in the form 
of a long-acting beta2 agonist (LABA) and inhaled corticosteroid (ICS), such as 
formoterol and budesonide (Symbicort) and salmeterol and fluticasone (Advair). 
However, worsening cases, particularly those that are allergic related and are refractory in 
this regard, may require add-on treatment in the form of monoclonal antibodies, such as 
omalizumab, which binds to and essentially inactivates IgE (immunoglobulin E), 
reducing its efficacy in manifesting hypersensitivity reactions. Other controller treatments 
include cromolyn sodium, methylxanthine derivatives, and leukotriene modifiers 
(National Asthma Education and Prevention Program, 2007). However, depending on 
treatment, concurrent complications observed in the patient may yield diminishing 
effectiveness of these medications or result in complete absence of improvement. 
Therefore, it is crucial that other potential maladies be revealed, particularly those of an 
inflammatory nature, so as to enhance the precision and utility of therapy.  
 
There are several comorbidities that have a particularly high association with asthma, 
enhancing the severity of the disease and thus making it more difficult to control, 
including obesity, gastroesophageal reflux, food allergy, rhinosinusitis, and psychiatric 
disorders, chief among these being anxiety and depressive disorders (National Asthma 
Education and Prevention Program, 2007, Mirabelli et al., 2016, Ullmann et al., 2018). 
According to Mirabelli et al., among asthma comorbid health conditions that are 
cardiovascular or metabolic in nature, such high cholesterol and hypertension, obesity has 
the highest prevalence among children aged 3-17. Obesity alone in the United States has 
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become an increasingly troubling pediatric disorder due to its systemic effects, 
particularly inflammation, and its complex pathology. Research has clearly demonstrated 
that obesity is a detriment to a child’s life, whether that is by increasing a child’s risk of 
incurring other cardiovascular, metabolic, or other dangerous diseases such as type 2 
diabetes mellitus and obstructive sleep apnea or by decreasing his/her current quality of 
life and life expectancy (Cole et al., 2013, Lloyd et al., 2012, Bacha et al., 2016, Narang 
et al., 2012, Morrison et al., 2015).  
 
Obesity is defined and diagnosed in a patient by calculating his/her body mass index 
(BMI) and comparing the value to that observed on average in the patient’s age and 
gender cohort. A child whose BMI is in the 95th percentile or greater or a BMI greater 
than or equal to 30 kg/m2, whichever is lower, is considered obese (Barlow et al., 2007, 
Styne et al., 2017). In U.S. children ages 2-19 years, the prevalence of obesity has 
increased by nearly 10% within a generation, from 10.0% in 1988-1994 to 18.5% in 
2015-2016, which is about 13.7 million children and adolescents (Ogden et al., 2018). 
Prevention of the disorder should be targeted to early in life before obesity onset, as 
incidence has been found to decline with age, with those preschool (0-4 years) and school 
age (5-12) having higher percentages, 4.0% and 3.2% respectively, then adolescents (13-
18), who have an incidence of 1.8% (Cheung et al., 2016).  
 
Because obesity also concomitantly increases risk of a wide-variety of serious chronic 
conditions, from atherosclerosis to psychiatric disorders, its economic impact is very 
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high. Lifetime incremental direct costs for pediatric obesity for just the 10-year-old age 
group, based on a modest per child figure of $19,000, is estimated to be $14 billion 
(Finkelstein et al., 2014). The upper estimate that the study found of $38,000 lifetime cost 
per 10-year-old obese child is equivalent to two years of public college tuition. The 
medicalization of obesity has resulted in an understanding that improving preventative 
techniques rather than its treatment possibly in the form of a pharmacological “cure” but 
typically in the form of surgical intervention is key. Hruby et al. asserts that high-yielding 
prevention of the disease in children could be brought about through implementation of 
an instructional program in healthy lifestyle and/or dietary modifications into the 
curricula of every primary and secondary school educational level. However, the study 
did recognize the vast resources needed to execute such an overhaul (Hruby et al., 2015). 
In 2013, the American Medical Association did alter their policy resulting a 
reclassification of “obesity” now making it a disease, which seems to imply that such 
allocation of resources to combat a disorder as dangerous and costly as obesity should be 
done to not only improve prevention but to enhance research of the disease and treatment 
modalities (Pollack, 2013). Nonetheless, promising obesity prevention and treatment 
approaches may be futile or less productive if the child is stricken with an ailment, such 
as asthma, that muddles such methods because it worsens or otherwise further 
complicates his/her obese condition. Therefore, it is paramount that comorbid conditions 




Several epidemiological and longitudinal studies, dating back to the late 1990s, have 
suggested that there is a strong association between obesity and asthma in children. An 
early study investigating the relationship between asthma and obesity in children and 
adolescents in urban communities with a highly diverse ethnic population discovered that 
among this pediatric demographic those who were obese or severely obese were almost 3 
times more likely to have asthma as compared to the controls (Gennuso et al., 1998). 
Additionally, a meta-analysis of several prospective studies demonstrated an increased 
odds ratio for asthma of 1.92 in those with obesity versus normal weight, meaning in 
essence, that being given a diagnosis of asthma was more likely to occur if a patient 
suspected of having the disease was obese (Beuther et al., 2007). Another meta-analysis 
performed by Chen et al. found that overweight children, defined as a having a BMI of 
equal to or greater than the 85th percentile, conferred a greater risk of incident asthma as 
compared with non-overweight children (Chen et al., 2013). This risk was discovered to 
be even more disparate in obese vs. non-obese children and boys vs girls. Furthermore, a 
dose-responsiveness of elevated BMI on asthma incidence was observed, meaning that as 
a child’s BMI above the 85th percentile increased, so did his/her risk for receiving a 
diagnosis of asthma. A Mendelian randomization study utilizing 32 independent body 
mass-related single nucleotide polymorphisms (SNPs) from a cohort of almost 5,000 
children found a significant causal relative risk for the effect of high adiposity on asthma 
of 1.55 (Granell et al., 2014). Instead of looking solely at BMI, which is a relatively 
insensitive indicator of adiposity, the researchers used independent SNPs that were 
directly associated with components of the obesity phenotype including, lean mass, fat 
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mass, and BMI, in order to provide a clearer picture of the relationship between asthma 
and obesity.  
 
The evidence here corroborates that obesity is an independent risk factor for and 
comorbid condition of asthma, however, there is substantial data in the literature that 
suggests that asthma concurrent with and, to at least some measure, precipitated by an 
obese state, or obesity-related asthma, is in fact a distinct disease state that possesses 
unique attributes, such as its own pathophysiology and clinical manifestations. Most of 
these discrete disease characteristics are more or less an amalgamation of those observed 
in each disorder separately, however when compounded, confer complexities that make 
treatment, at best, difficult. In a report written by the American Thoracic Society 
workshop in 2010, they asserted that “asthma in the obese may represent a unique 
phenotype of asthma, with more severe disease that does not respond as well to 
conventional therapy” (Dixon et al., 2010). Asthma and obesity alone already are 
significant health epidemics among children in the United States, and even though it 
represents a small subset of either patient population, obesity-related asthma, due to its 
indirect and direct costs such as hospitalization and primary school absenteeism, wrought 
a substantial problem to the health care industry in terms of fiscal expenditure, and most 
importantly, a child’s future quality of life and potential. Therefore, it is of critical 
interest to determine pathologically how the disease affects the body and the current 





The first goal of this thesis is to educate the audience on pediatric asthma, including 
delineating its epidemiology, economic burden, primary signs and symptoms, diagnosis, 
and the normal modalities of treatment/management. Following this, my plan is to share 
with the audience the problematic and alarming epidemic that is childhood obesity and, 
as with pediatric asthma, detail its epidemiology, etiology, its effects on quality of life, 
and its association with pediatric asthma. Finally, I will be presenting and discussing the 
following aspects of obesity-related asthma: major postulated phenotypes, 
pathophysiological mechanisms, and therapeutic strategies and interventions.  
 
Potential Phenotypes 
In the literature, there appears to be definitively two asthma phenotypes that are highly 
associated with obesity, and thus have been formally classified as the primary obesity-
related asthma phenotypes (Dixon et al., 2016, Bates et al., 2017, Diaz et al., 2014). 
These are early onset, atopic (EOA) and late onset, non-atopic (LONA) obesity-related 
asthma. The EOA phenotype is characterized by asthma symptoms that are more severe 
and begin before 12 years of age, affecting male and female patients equally, high 
immunoglobulin E (IgE) antibody and Th2 (T helper cell type 2) cytokine levels, and 
acutely decreased airway function determined by forced expiratory volume in 1 second 
(FEV1) and forced vital capacity (FVC) parameters. Atopic is used to describe a 
condition related to atopy, which refers to the genetic tendency to produce allergic or 
hypersensitivity reactions such as dermatitis or asthma in response to exposure to 
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environmental antigens such as pollen and an increase in blood IgE specific to 
predisposed antigens is a consistent biomarker of this condition (Wenzel, 2012). LONA 
obesity-related asthma is mostly observed in females and patients after 12 years of age 
lacking any atopic characteristics, lower Th2, IgE and eosinophilic levels, higher 
neutrophilic count and asthma medication use, less severe symptoms, and better airway 
function. The literature suggests that the LONA subtype more commonly found in 
teenagers and females is initially caused by an obese condition that antedates the 
development of asthma. 
 
Several mechanisms may underlie the obesity-asthma disease pattern, some of which are 
unique to the aforementioned subgroups of the disorder, which induce the development 
of asthma or further aggravate a pre-existing asthma condition. These mechanisms 
include obesity-driven modification of pulmonary function due to increased truncal fat 
load, obesity-related systemic inflammation that alters lung reactivity, mitochondrial 
dysfunction and oxidative stress, and obesogenic syndromes, such as diabetes and 
dyslipidemia. Furthermore, immunomodulatory effects of obesity, mediated by adipose 
tissue-specific cytokines, known as adipokines, which include leptin and adiponectin, 
have also been hypothesized to inspire asthma in obese children or physiologically 
complicate an already diagnosed asthma pediatric. Beyond the direct and indirect effects 
of this disease in children, there is a clear need for better identification of biomarkers in 




EOA-SPECIFIC PATHOLOGICAL MECHANISMS 
 
Atopic Inflammation 
The pathogenesis of the early-onset asthma phenotype involves a Th2-mediated, or type 
2, inflammatory pathway that begins with allergen sensitization in the airways and 
eventually results in chronic inflammation, airway remodeling and obstruction, all of 
which contribute to the clinical manifestations of asthma. The Th2-mediated 
inflammatory pathway is heavily dependent upon the cytokines IL-4, IL-5, and IL-13, 
which are secreted by cells that appear at the onset of this immune response process and 
importantly stimulate other cells and underlying mechanisms vital to the full 
manifestation and persistence of this type of inflammation (Holgate, 2008). These type 2 
cytokines drive multiple downstream events in this specific inflammatory process, 
including chemoattraction of mast cells, eosinophils, and basophils, ultimately resulting 
in an inflammatory state, and transformation of the epithelium and subepithelial tissues 
(Holgate, 2008). A few of the master regulators of type 2 inflammation are IL-33, IL-25, 
or thymic stromal lymphopoietin, which primarily are involved in the upstream processes 
that include the maturation of naïve T cells into Th2 cells and the production of type 2 
cytokines (IL-4, IL-5, and IL-13) (Holgate et al., 2015).  
 
Airborne allergens, such as pollen, animal dander, dust mites, and mold, elicit responses 
both in airway epithelial cells and dendritic cells that act as antigen presenting cells and 
possess long cytoplasmic processes that protrude into the airway space and contain 
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pattern recognition receptors (PCRs) specific to an allergen. The PCRs on airway 
epithelial cells, such as Toll-like receptor 4, bind the particular allergen and are then 
stimulated to release IL-25, IL-33, thymic stomal lymphopoietin (TSLP), and 
granuclocyte-macrophage colony stimulation factor (GM-CSF), which recruits and 
activates dendritic cells, among other cells like eosinophils and T lymphocytes activated 
by these chemokines and cytokines (Ishmael, 2011). These dendritic cells locally attract 
eosinophils and migrate through the lymphatic system to regional lymph nodes, the 
chemotaxis of which is mostly mediated by CCL19 and CCL21 via CCR7, where they 
contact and stimulate the differentiation of naïve T cells into Th2 cells in the presence of 
a high ratio of IL-4 to IL-12. These Th2 cells then migrate back to the airways under the 
influence of chemokines such as CCL11 and CCL22 and produce a variety of cytokines, 
IL-4, IL-13, and IL-5 being of particular importance to the asthma pathology (Holgate 
2008). IL-13 and IL-4, which also causes the differentiation of premature T lymphocytes 
already in the airway mucosa to Th2 cells, both stimulate B cells to bind Th2 cells 
through the CD40 receptor-ligand complex upon which they then secrete IgE, which not 
only plays a vital role in the immunological memory facet of asthma in part by binding to 
and enhancing dendritic cell response to particular allergens but also elicits degranulation 
of mast cells and basophils (Holgate et al., 2015). Dependent on stem cell factor (SCF), 
which is produced by airway epithelia, smooth muscle, and fibroblasts, for its survival, 
mast cells upon degranulation release heparin, leukotriene, histamine, and prostaglandin. 
These mediators are central to the inflammatory state that is fundamental to asthma, 
directly by causing vasodilaton and bronchoconstriction and indirectly by serving as 
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chemoattractants for other pro-inflammatory cells such as macrophages and eosinophils. 
Mast cells also are recruited to the deeper portion of the airway into the smooth 
musculature by CXCL8 and CXCL10, where they are stimulated to secrete CCL19, 
which causes smooth muscle hyperplasia and migration, resulting in airway mucosal 
remodeling, which ultimately negatively affects breathing capabilities as observed in 
asthmatic patients (Holgate et al., 2015). Tryptase, a secretory product of mast cells, has 
preferential action on a receptor present on epithelial, endothelial, fibroblast, and smooth 
muscle cells of the airways known as PAR2, which upon activation is involved in 
mesenchymal cell proliferation and thus remodeling of the airway connective tissue 
(Holgate et al., 2015).  The third chemokine seemingly obligatory to asthma pathology is 
IL-5, which first completes the maturation process of eosinophils from their bone marrow 
precursors, CD34 cells, and then maintains their survival. Initially, IL-3, GM-CSF, 
eotaxins 1-3, and macrophage chemotactic factors 3-4 attract and prime the CD34 cells to 
the area of inflammation and Th2 cell abundance by interacting with CCR3 and CCR5 
cellular receptors (Ishmael, 2011). Eosinophils not only support inflammation by 
releasing granules, upon the stimulation, consisting of prostacyclin, leukotrienes, 
superoxides, peroxidase, and cationic proteins, but they also contribute tissue remodeling 
by producing transforming growth factor (TGF)-beta 1 and enhancing fibroblast 
proliferation, collagen synthesis, and myofibroblast maturation. These pro-inflammatory 
cells and their unique contributions to the asthma pathology, specifically airway 
remodeling and inflammation, are initiated by an allergen-dependent response system, 
which becomes increasingly sensitive due to the effects of IgE-dendritic cell binding, and 
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driven by the Th2-mediated inflammatory pathway that becomes self-reinforcing due to 
the release of chemokines and cytokines both by the Th2 cells and their successor cells 
that ultimately results in a chronic inflammatory state of the airway mucosa (Ishmael 
2011). 
 
Mitochondrial Dysfunction and Oxidative Stress 
Oxidative stress and mitochondrial dysfunction are particularly important to the 
pathology of the EOA phenotype as the effects of both physiological complications were 
mostly reported in the early-onset, atopic form of the disease. Specifically, EOA is 
characterized by an allergic-driven inflammatory pathology and results from several 
studies have suggested that oxidative stress and mitochondrial dysfunction brought to a 
body-wide scale may increase Th2-related pro-inflammatory biomarkers in the airway 
mucosa thus contribution to a more severe disease pattern based on inflammation. 
Mitochondrial dysfunction and eventual subcellular damage results initially from 
nutritional overload, which leads to excess electron flux and increased oxidative stress, 
all three of which can be traced back to caloric excess and consumption of a high fat diet, 
two of the most common causes of obesity (Koves et al., 2008, Watt et al., 2008). 
Because mitochondrial function dictates much of the utility and maintenance of many 
other important metabolic pathways, particularly amino acid metabolism, rising 
intracellular oxygen and oxidative stress accompanied by or resultant of mitochondrial 
dysfunction, eventually leads to an increase in harmful metabolites, such as homocysteine 
and asymmetric dimethyl arginine (ADMA), which is an intracellular metabolite 
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byproduct of mitochondrial dysfunction that directly inhibits nitric oxide synthase 
causing oxidative stress in tissues (Pattnaik et al., 2016). Cellular metabolism obviously 
affects every cell type in the body. Thus, when dysfunctional mitochondria are rampant 
in the tissues of the most vital metabolic organs in body, such as the liver and pancreas, a 
systemic imbalance in metabolic products and reactants leads to mitochondrial 
dysfunction in peripheral and other tissues, including and most importantly, airway 
epithelia.  
 
Using an allergic asthma model in mice, Mabalirajan and associates discovered that 
mitochondrial dysfunction in airway epithelium was a key feature of the pathogenesis of 
the disease (Mabalirajan et al., 2008). Using the same murine model, another team led by 
Aguilera-Aguirre also determined that mitochondrial dysfunction worsens the severity of 
asthma (Aguilera-Aguirre et al., 2009). Very high levels of ADMA were found in 
allergically inflamed lungs as part of a study conducted by Pattnaik and colleagues, in 
addition to the finding that IL-4, a characteristic type 2 inflammation cytokine, was 
significantly upregulated. Interestingly, IL-4 also increased ADMA synthesis while 
simultaneously inhibiting its degradation (Pattnaik et al., 2016). This combination of IL-4 
and ADMA strongly stimulated oxidative stress and, as expected, the cellular hypoxic 
response, which causes the transcriptional repression of mitochondrial biosynthesis. 
Undue activation in high frequency of the hypoxic response led to a severe asthma 
phenotype, a study observed, where some of the mice developed fatal 
bronchoconstriction during challenge testing (Ahmad et al., 2012). In the same study, the 
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researchers confirmed that both IL-4 and ADMA led to disintegration of mitochondria, 
increased release of mitochondrial reactive oxygen species (ROS), and decreased 
mitochondrial content in airway epithelial cells, all of which most likely contributed to 
the terminal asthma disease type. Not only does this result in cellular and tissue damage 
causing further airway inflammation, the accompanying increased oxidative stress 
present in the airway epithelia, typically measured by increased 8-isoprostanes in exhaled 
breath condensate, is also associated with decreased airway nitric oxide, which has 
important bronchodilatory and homeostatic functions in the airway (Singh et al., 2015). 
These studies suggest that obesity, with intrinsically high ADMA levels and a conferment 
of increased risk for systemic mitochondrial dysfunction, and type 2 inflammatory 
associated with atopic asthma, with increased IL-4 levels, would act synergistically and 
lead to a heightened state of mitochondrial dysfunction. In regards to potential treatments 
stemming from this aspect of pediatric obesity-related asthma, a report was made based 
off a murine model of allergic asthma, that showed that high-dose arginine 
supplementation inhibited the mitochondrial dysfunction and attenuated asthma features 
(Mabalirajan 2010). This is corroborated by previous studies that also demonstrated the 
effectiveness of high-dose arginine supplementation to reverse ADMA-induced 
mitochondrial dysfunction and epithelial damage in obesity-related metabolic syndrome, 
a complication which will be discussed later that has a strong association with asthma, 
signifying that this could be a key juncture for both diseases (Stuhlinger et al., 2005). 
Although the material presented above is suggestive of it, the EOA phenotype has been 
reported as manifesting with high levels of ADMA (Holguin et al., 2013). The literature 
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provides a clear picture on the most important pathologic components specific to the 
obesity-related EOA phenotype, which is a typical atopic asthma condition exacerbated 
by underlying systemic mitochondrial dysfunction conferred by obesity that reaches the 
airway mucosa.  
 
LONA-SPECIFIC PATHOLOGICAL MECHANISMS 
 
Pulmonary Mechanics 
The literature suggests that the LONA phenotype typically presents with little airway 
inflammation and instead, there is decreased lung volumes, heightened sensitivity to 
airway closure, and increased airway obstruction. Obesity is characterized by adipose 
tissue hypertrophy and increasing amounts of abnormally large fat deposits around the 
body, particularly in the trunk area. An excessive amount of adipose tissue located in the 
trunk can confer a mechanical detriment to the diaphragm due to an increased mechanical 
load. In LONA, excess truncal adiposity is directly correlated with decreased expiratory 
reserve volume (ERV), functional residual capacity (FRC), and residual volume (RV) 
(Rastogi et al., 2012, Rastogi et al., 2014, Davidson et al., 2014, Li et al., 2003). Even 
though obese children have increased forced vital capacity (FVC) and forced expiratory 
volume in 1 second (FEV1) than their counterparts within the normal BMI range, the 
recipe of restricted pulmonary mechanics and reduced lung volumes results in children 
who are obese presenting with lower FEV1/FVC ratio, which is a much more important 
quantitative parameter in regards to lung function and consideration for an asthma 
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diagnosis (Vo et al., 2013, Rastogi et al., 2012, Tantisira et al., 2003;,Spanthopoulos et 
al., 2009, Chu et al., 2009). Additionally, a lower FRC may decrease bronchial smooth 
muscle stretch resulting in the discernment of increased respiratory effort even though a 
normal inspiratory pattern is observed (Salome et al., 2010). Indeed, breathing at low 
lung volumes has been considered as leading to dangerously amplified actin–myosin 
cross-linking in airway smooth muscle, resulting in muscle stiffness in the lungs and 
making them much less compliant (Fredberg et al., 2000). Airway smooth muscle stretch 
has been observed as a crucial factor in the development of disease-related airway 
reactivity in vivo. Interestingly, in vitro analyses have revealed that airway smooth 
muscle stretch alters the expression of proteins in on the myocytes themselves. 
Furthermore, it has been shown that continuous positive, outward airway pressure against 
the walls of the bronchioles leads to decreased airway reactivity in animal asthma models 
and asthmatics (Busk et al., 2013). Additionally, breathing at the low lung volumes as 
part of a restrictive lung pattern resulting from an obese comorbidity leads to increased 
airway hyperresponsiveness (AHR), also known as bronchial or airway hyperreactivity, a 
characteristic feature of asthma that is an increased sensitivity of the airways to an 
inhaled constrictor agonist, a steeper slope of the dose-response curve, and a greater 
maximal response to the agonist (Skloot et al., 1995). Along with inspiratory flow 
limitations arising from an increased load, dysfunction of expiratory flow also results 
from such a mechanical disadvantage, which can cause a reduction in usable lung 
volume, a quality often observed in asthma. Obese individuals present with certain 
breathing capacities that are close to the closing volume of the airways, which may 
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stimulate reduction in usable lung volume. Additionally, any prolonged period of 
bronchoconstriction will increase this expiratory flow limitation during tidal breathing 
and further increase this physiological dead space (Mahadev et al., 2013). This impulsive 
airway closure observed in those with obesity may have considerable effects on airway 
caliber and function in the setting of the LONA phenotype. 
 
Inflammasomes 
Although, the most important pathological component of asthma is airway inflammation, 
there appears to be little inflammation driven by the classical components as seen in the 
atopic-related EOA phenotype based on studies that corroborate low Th2, IgE, 
eosinophilic markers in LONA. Still, in this regard, systemic inflammation is a necessary 
component of an obesity disease pattern, which may ultimately result in the trafficking of 
certain pro-inflammatory cytokines and chemokines into the lungs, creating 
inflammation, albeit not as severe as in EOA, and thereby altering function. The low 
grade, chronic inflammatory feature of obesity is multifactorial and although “low 
grade,” is highly impactful systemically. Inflammation in adipose tissue is primarily 
initiated by the release of danger-associated molecular patterns and other inflammatory 
moieties in adipocyte tissue necrosis, which can result from adipocyte hypertrophy via 
enlargement of intracellular lipid droplets, delayed neovascularization and thus hypoxia 
due to adipose tissue hyperplasia including expansion of its stromal vascular fraction 
containing immune cells and macrophages, and metabolic dysfunction of adipocytes 
(Ellulu et al., 2017). The greatest contributors to the continual inflammation in obesity 
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and the predominant result of these instigating factors are structures known as 
inflammasomes. Inflammasomes are multiprotein complexes that polymerize when 
activated by byproducts of cellular damage, such as, uric acid crystals, cholesterol 
crystals, extracellular ATP, low intracellular potassium concentrations, and conserved 
pathogen characteristics such as foreign cytoplasmic double-stranded DNA and other 
viral and bacterial elements (Umetsu 2016). The most prominent of these activated 
inflammasome complexes, is NLR family, pyrin domain containing 3 (NLRP3), which 
when triggered, cleaves procaspase 1, which in turn cleaves pro-IL-1β and IL-18, driving 
inflammation in many organs in which NLRP3’s are present by directly damaging tissue 
or by mediating the trafficking of lymphocytes and pro-inflammatory M1 macrophages 
mostly to the adipose tissue and to a lesser degree around the body (Umetsu 2016). In 
obesity, NLPR3s are primarily created and triggered by lipid derivatives such as 
palmitate, stearate, free cholesterol, and cholesterol crystals, all of which are released 
upon necrosis of adipocytes.  
 
A murine model study recently done has shed some light on the exact mechanics in 
which these inflammasomes that arise from pre-existing obesity may contribute to a late-
onset asthma pathogenesis. In the report, the mice were fed a high-fat diet beginning at 3 
weeks of age, and were continued on this diet for 12 weeks until they became obese, at 
which point they all expectedly developed AHR, without presenting to or initiation with 
allergens (Kim et al., 2014). This suggests that unlike most models of asthma, neither 
allergen-specific Th2 cells nor IgE was required for the development of AHR because the 
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AHR associated with the development of obesity in the mice, which were Rag1−/− mice 
thereby genetically lacking B and T lymphocytes, the mediators of immunological 
memory, was independent of humoral immunity. Additionally, consistent with the 
concept presented here that the LONA phenotype is allergen-independent and contains 
low Th2 biomarkers, such as eosinophils, as reported in the categorization studies and 
meta-analyses, there were few eosinophils found in the airways of the Rag1−/− mice. 
Furthermore, AHR did not arise in obese Nlrp3−/− or Il17a−/− mice, even though it did 
in control wild-type obese mice, demonstrating that NLRP3 and IL-17A might both be 
vital to the pathogenesis of late-onset asthma in the obese (Kim et al., 2014). In the lungs, 
the cells that produce IL-17 are T cells that do not express the regular and conventional 
T-cell or immunoglobulin receptors, but instead express CCR6, CD44, Sca-1, and ROR-
γt, all of which are markers of type 3 innate lymphoid cells (ILC3s), which belong to a 
family of recently described effector cells that can quickly biosynthesize and secrete great 
amounts of cytokines, mostly IL-17 and IL-22, both of which are involved in 
autoimmune diseases and may cause cellular damage in the airway contributing to an 
asthma pathogenesis. ILC3s respond to IL-1β, whose secretion is induced by NLRP3 
activation, and in the study the researchers examined the treatment of mice with 
recombinant IL-1β, which, surprisingly, by itself produced AHR, even in the absence of 
humoral immunity-related elements or type 2 cytokines (Kim et al., 2014). Finally, 
inhibition of IL-1β signaling in the obese mice using an IL-1 receptor antagonist 
eliminated obesity-associated AHR and decreased the number of ILC3s, signifying a 




In the lungs of obese mice, IL-1β was manufactured chiefly by M1 macrophages, which 
were found in large amounts, unlike the lungs of the lean mice. Inspection of the 
bronchoalveolar lavage (BAL) fluid from a small subset of patients with severe asthma 
confirmed the presence of ILC3s, clearly indicating that ILC3s producing IL-17 have a 
vital function in human asthma pathology (Kim et al., 2014). It is important to note that 
M1 macrophages are known to generate IL-1β and IL-6, whose increased production is 
another feature of metabolic dysfunction and severe asthma in obese patients (Peters 
2016). Together these studies suggest that the NLRP3 inflammasome, IL-1β and IL-17-
producing ILC3s, all stimulated or distinctly upregulated in obesity, may comprise a 




Studies have found that obese adolescents possess a greater percentage of sputum 
neutrophils than their nonobese counterparts and that, in females, BMI is positively 
correlated with sputum neutrophils, which substantiates the findings here that the LONA 
phenotype occurs more often in older, female children and that there is much greater 
neutrophilic infiltration in the airways (Telenga et al., 2012, Scott et al., 2011, Haldar et 
al., 2008). In a cluster analysis study, Haldar and colleagues found an asthma phenotype 
characterized by late-onset of asthma-related symptoms and pathological manifestations, 
obesity, and noneosinophilic inflammation of the airways. The subjects were mostly 
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female, had an increased number of sputum neutrophils, and a decreased number of 
sputum eosinophils. The increased neutrophilic inflammation in obese asthmatics may be 
a result of the M1 macrophages, which make up a significant portion of the stromal 
vascular fraction of adipose tissue, that produce and release several pro-inflammatory 
mediators, including TNF-a (Arango Duque et al., 2014). The chronic low-grade 
systemic inflammation that results from an obese condition as indicated by increased 
migration of T cells in circulation and blood plasma levels of C-reactive protein may 
eventually result in the creation of local inflammation in asthmatic airways and an 
increased but not overwhelming presence of M1 macrophages in the lungs, leading to 
more neutrophilic inflammation in this region (Van Hemelrijck et al., 2011, Gogo et al., 
2005). Increased amount of gene products related to the TNF-a pathway is strongly 
connected to an increase in neutrophilic inflammation in the sputum of asthmatics, 
therefore, TNF-a could be directly liable for the conscription of neutrophils to the 
bronchioles. As these studies demonstrate, neutrophilic inflammation is found more often 
in female patients, in the context of obesity-related asthma, which may be due to a 
disparity in body composition between obese men and women, who have a greater 
percentage of subcutaneous adipose tissue (Blaak et al., 2001, Karastergiou et al., 2012). 
This type of adipose tissue is more metabolically active then visceral adipose tissue 
resulting in an increase in pro-inflammatory mediators specifically those that prime and 
activate neutrophils, which potentially may find their way to the lungs, thus contributing 
to airway inflammation and augmenting their percentage in sputum as seen in this 




As described, this particular obese asthma disease pattern owns a clear set of distinct 
clinical characteristics that seems to indicate that the development of asthma and asthma-
like symptoms in an older pediatric age group arises from an antecedent obese condition. 
These characteristics include a higher prevalence in females, hampered lung mechanics, 
and increased adipose tissue-specific inflammatory entities leading to an increased AHR 
and decreased pulmonary functioning. Now, it is important to consider the question of 
why obesity doesn’t transform every adolescent into an individual with late-onset, non-
atopic asthma. Many potential answers to this question may exist, including how there 
may be genetic differences in susceptibility between individuals that makes one more 
prone over the other to have a disproportionately larger increase in hyperresponsiveness 
for the same reduction in lung volume. A study examining this possible answer, 
specifically the degree of interindividual variation in airway wall stiffness due to genetic 
predisposition, found that as lung volume becomes increasingly reduced with advancing 
weight, there is a slow but steady increase in the proportion of the population with more 
than average compliant airways that becomes hyperresponsive to challenge testing (Bates 
et al., 2015). It is plausible that when considered in the context of worsening obesity, this 
particular population presents with an increasing prevalence of asthma-like symptoms 
and, ultimately, asthma, whereas most members of the normal population have intrinsic 
airway rigidities that are uncomplicated at normal weight. Another interesting answer is 
how the additional adipose tissue inherent to an obese condition is spread around the 
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body. Preferential distribution to the buttocks would certainly have little effect on 
compressing the lungs or conferring a mechanical load that would reduce volume.  
 
MECHANISMS UNDERLYING BOTH PHENOTYPES 
 
Although each obesity-related asthma phenotype in children harbors their own unique 
array of pathological qualities, there exists several underlying mechanisms shared by both 
that contribute to disease complexity and treatment difficulty, such as dyslipidemia, 
insulin resistance, cytokine milieu, gut microbiome, and weight loss, all of which will be 
discussed. Dyslipidemia, metabolic syndrome, and insulin resistance are all measures of 
metabolic dysregulation that arise in most pediatric obese patients (Al-Shawwa et al., 
2007, Cottrell et al., 2011, Al-Shawwa et al., 2006, Del Rio Navarro et al., 2010, Lee et 
al., 2006, Korsten-Reck et al., 2008). Additionally, several genetic and epigenetic 
disparities in molecules implicated in metabolic dysregulation and the inflammation that 
develops specifically from it have been discovered in the pathological environment of 
obesity-related asthma. Below, these better-investigated physiological mechanisms of 
pediatric obesity-related asthma will be summarized. 
 
Adipokines 
Leptin and adiponectin are the two most significant cytokines released by adipose tissue, 
in terms of quantity produced and released, and thus constitute the chief adipokines. 
Related clinical research has uncovered that decreased adiponectin and increased leptin 
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levels in obese children compared with their nonobese counterparts with asthma, 
potentially signifying that obesity-induced changes in the systemic cytokine 
neighborhood may be responsible for the development of asthma in children (Mai et al., 
2004, Rastogi et al., 2012, Yuksel et al., 2012, Nagel et al., 2009). As adiposity increases, 
plasma leptin concentration increases and plasma adiponectin decreases, two major 
cytokines that have been associated with the pathology of pediatric obese-asthma (Dixon, 
2009). Leptin is readily detected in the airways, is higher among asthmatics, and 
increases in relation to plasma leptin levels and BMI (Holguin et al., 2011, Lugogo et al., 
2012). With increased plasma leptin, there is enhanced T lymphocyte proliferation as 
well as increased pro-inflammatory cytokines interferon-γ (IFN-γ), interleukin (IL)-6, 
and tumor necrosis factor (TNF) production contributing to inflammation in pediatric 
obesity-related athma. (Ferrante et al., 2013). Additionally, airway epithelial cells express 
leptin receptors, which are associated with airway remodeling changes, a common 
pathological trait of asthma (Bruno et al., 2009). In the periphery, the upregulated 
expression of leptin receptors in visceral adipose tissue reportedly is associated with the 
development of AHR, which has led to the hypothesis that obesity-related asthma is more 
so a disease of peripheral, not truncal adipose tissue (Sideleva et al., 2012). In one study, 
leptin was observed as increasing the inflammatory response of alveolar macrophages 
derived from obese asthmatics (Lugogo et al., 2012). In an murine asthma model, leptin 
was reported to increase AHR and serum IgE, a component of the EOA phenotype (Shore 
et al., 2005). Conversely, adiponectin is postulated to have protective, anti-inflammatory 
effects in obesity-related asthma. Murine studies have shown that it functions to inhibit 
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allergic airway inflammation and airway reactivity, an activity that appears to be related 
to its serum levels (Shore et al., 2006, Verbout et al., 2013, Williams et al., 2012). In 
human females, a study concluded that increased plasma adiponectin is linked with 
decreased asthma risk, however, it remains to be determined if adiponectin has any 
distinctive immunomodulatory effects in the lungs (Sood et al., 2008).   
 
Insulin Resistance 
A review of the latest relevant research suggests that insulin resistance plays a role in 
obesity-related asthma in children. In pediatric asthma, higher prevalence and severity of 
insulin resistance and metabolic syndrome have been described as compared with non-
asthmatics (Al-Shawwa et al., 2007, Cottrell et al., 2011, Del Rio Navarro et al., 2010, 
Arshi et al., 2010). The pro-inflammatory adipokines leptin and IL-6 are very indicative 
of the presence of insulin resistance, which has been established as a predictor of airway 
obstruction and reduced lung volume, two qualified measures of lung function 
deficiencies frequently observed in asthma (Arshi et al., 2010, Rastogi et al., 2014).  
 
A mechanism born from insulin resistance that is believed to contribute to diminished 
pulmonary function and potentially the development of asthma is systemic inflammation. 
Outside of its primary role in glucose metabolism, insulin also possesses anti-
inflammatory capabilities (Hyun et al., 2011). Excessive exogenous insulin 
administration has been linked with a diminution of lipopolysaccharide-induced lung 
injury in a mouse model, with accompanying decreases in TNF, IL-1β, and IL-6 in the 
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BAL (Liu et al., 2012). A very common pathological consequence of obesity is 
attenuation of insulin signaling, eventually leading to insulin resistance. This disruption 
in signaling can lead to adipose-related inflammation resulting in the activation of Th1 
cells and macrophages (Lumeng et al., 2011). Rastogi and colleagues discovered that the 
relationship between systemic Th1 polarization and obesity-mediated impaired lung 
functionality among ethnic minority children may be mediated by insulin resistance, 
lending to the decreased Th2 biomarker characterization of the LONA phenotype 
(Rastogi et al., 2015). It is clear that a strong association exists between insulin 
resistance, inflammation, and pulmonary function impairment, however, further 
examination of the immunometabolic pathway that connects these potential comorbidites 
is crucial to the goal of conclusively determining the mechanism(s) through which insulin 
resistance contributes to pediatric obese-related asthma. 
 
A second mechanism onset by insulin resistance that has been considered as being partly 
responsible for the development of asthma in an obesity context is the effect insulin 
exerts on airway smooth muscle (ASM). Insulin resistance has been patently established 
as increasing airway hyperresponsiveness (AHR), a key physiological feature of asthma, 
by increasing ASM contractility (Dekkers et al., 2009). Hyperinsulinemia, a cause of 
insulin resistance, increases laminin expression, which is a known molecular driver that 
signals smooth muscle myocytes to contract, in cow airway smooth myocytes via a 
phospho-inositide-3 kinase (PI3K)/Akt dependent pathway (Dekkers et al., 2009). 
Insulin-like growth factor, which has been reported to be associated with ASM 
	
28 
hyperplasia, is always vastly upregulated in an insulin resistant condition (Noveral et al., 
1994). Additionally, insulin may increase AHR by affecting parasympathetic ganglions, 
suggested by an obese rat model study (Nie et al., 2014). Now that obvious indications 
have been made by these initial studies that the hyperinsulinemia component of insulin 
resistance effects AHR by altering ASM contractility, translational studies involving 
obesity-related asthma are needed to further elucidate the role of each of those 
aforementioned pathways in ASM cells. A more comprehensive understanding of these 
pathways could potentially sanction the use of metformin, which is customarily used to 
treat standalone insulin resistance, in a management plan for pediatric obesity-related 
asthma (Bossé et al., 2014). 
 
Dyslipidemia 
Similar to insulin resistance, a relationship has been characterized between dyslipidemia 
and asthma in children (Cottrell et al., 2011). High-density lipoprotein (HDL), which has 
been colloquially described as being vital to maintaining a proper level of “good” 
cholesterol in the body, has been determined to have a shielding effect on pulmonary 
function parameters in obese pediatrics through its influence on monocyte activation, 
meaning HDL partly prevents obese children from experiencing impaired lung function 
commonly observed in these patients (Rastogi et al., 2015). Mounting evidence suggests 
that the pathological connection between pulmonary morbidity and diet-induced 
metabolic dysregulation may begin in gestation. One study demonstrated that maternal 
sustained low intake of fatty acids is in fact positively correlated with an elevated 
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predilection in the progeny to asthma (Lumia et al., 2011). This indicates that altered fat 
intake and dyslipidemia may be risk factors for AHR and airway inflammation, and 
ultimately may be involved in the development of the EOA phenotype (Cottrell et al., 
2011). A meal high in fats, consisting mostly of triglycerides and little HDL, 
commensurately increased levels of FeNO, a biomarker that strongly indicates airway 
inflammation (Rosenkranz et al., 2010). Interestingly, Wood and others found that high 
fat intake in adolescents was accompanied by increased neutrophilic inflammation in the 
airways and a markedly diminished response to bronchodilators (Wood et al., 2011). 
Additionally, high-fat diets that may lead or exist in conjunction with dyslipidemia make 
the lung prone to oxidative cellular damage and inflammation because they are typically 
coupled with decreased consumption of antioxidants (Wood et al., 2009).  
 
The Gut Microbiota 
The colon holds a tremendously vast and diverse throng of microbes, jointly known as 
the gut microbiota. These microbes mostly are bacterial species under the Actinobacteria, 
Bacteroidetes, Fusobacteria, and Proteobacteria phyla (Blaunt et al., 2013). In obese 
patients, distorted ratios of Bacteroidetes to Firmicutes have been reported, however, 
there are studies that dispute this. Gut microbiota has been thoroughly established as 
having a significant effect on several important physiological functions and is a very 
important player in human gastrointestinal tract health, development, metabolism, and 




According to the “hygiene hypothesis”, many disorders such as autism and the allergy 
epidemic arise from elements that in some way change the gut microbiota (Kumari et al., 
2016). The vast majority of the microbiota develops primarily during early childhood, 
and recently a tremendous amount of evidence has been gathered that indicates the 
presence of a significant linkage between the maladaptation and imbalance of the gut 
microbiota, also known as dysbiosis, and the pathogenesis of diseases such as obesity and 
asthma (Marchesi et al., 2016). Many causes such as mode of delivery, infant diet, and 
antibiotics effect the colonization of the colon by certain microbes. For example, one 
study characterized the differential growth and occupation of bacteria in the infant gut by 
comparing the use of breast milk versus formula (Gomez-Llorente et al., 2013). 
Additionally, it was found that within the first 6 weeks of life, the modifications that the 
gut microbiota experiences are less affected by mode of delivery and more so by body 
site (Chu et al., 2017). 
 
Antibiotics are well-established as an element that has a precipitous effect on the 
composition and development of the gut microbiota. Numerous studies suggest the 
presence of a correlation between obesity in children and early exposure to antibiotics, 
including a recently completed large, population-based cross-sectional study, which 
affirmed the effect that antibiotic use in male neonates resulted in increased BMI later in 
childhood (Murphy et al., 2014). It has been observed that the use of antibiotics in young 
children does result in distinct modifications to the gut microbiota composition that is 
sustained over 6 months. Korpela and associates determined that a positive correlation 
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exists between lifetime antibiotic use, specifically macrolide, and BMI, as well as an 
elevated chance of being diagnosed with asthma (Korpela et al., 2015). Finally, the 
conclusions made from a study that examined the use of vancomycin to treatment Th2 
model of allergic asthma in neonates seems to suggest that changes to the makeup of the 
colon microbiota may influence disease severity (Russell et al., 2015).  
 
The gut microbiota has an important role in maintaining intestinal integrity, and the 
primary mediator of this interaction is immunoglobulin A (IgA), the most common 
antibody secreted by the intestine and colon. IgA secreted by the colon and intestine, 
known as secretory IgA (sIgA), binds bacterial antigens and, by yet to be distinguished 
mechanisms, limits growth and exerts selectiveness of particular bacterial species, 
thereby promoting diversity of the microbiome. Pediatric allergic disorders present with a 
lower fraction of IgA at 12 months of age that may suggest a diminished mucosal barrier 
(Dzidic et al., 2017). Additionally, a study found that excessive fecal calprotectin levels, 
a biomarker for inflammation in the intestines, at 2 months of age accurately forecasted 
an asthma diagnosis at 6 years of age (Orivouri et al., 2015).  
 
Included among the diverse and important functions of the gut microbiota is increasing 
the concentration of short chain fatty acids (SCFAs), which chiefly are acetate, butyrate, 
and propionate. SCFAs have been shown to outline the immunological environment of 
the lung and impact the severity of allergic inflammation (Trompette et al., 2014). 
Importantly, altered profiles of fecal SCFAs have been linked to the development of 
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obesity, but this connection is partially justified by the gut microbial profile and its 
interacting mechanisms. Additionally, the development of asthma has been associated 
with the SCFAs produced by the gut microbiota, and SCFAs have been discovered to be 
influencing other physiological processes, such as fat metabolism, suppression of 
appetite, and immunity in the gastrointestinal tract. Finally, the receptors for these SCFA 
are extensively dispersed amongst the microbes that constitute the microbiota here and 
may be comprise a promising and possibly significant arena for pharmacotherapeutic 
targets (Kumari et al., 2016, Hartstra et al., 2016).  
 
As part of its function in preserving the integrity of the intestines integrity, the gut 
microbiota aids in the inhibition of endotoxemia, a low-grade inflammatory condition 
that arises from the release and trading of lipopolysaccharides (LPS) from different 
species of gram-negative intestinal bacteria. Through this condition, metabolic disorders 
such as insulin resistance can more easily come about and be sustained, which, as 
described earlier, can increase the severity of and complicate asthma (Hartstra et al., 
2016). Vatanen and colleagues discovered that Estonian neonates contained in their gut 
microbiota a higher fraction of Bacteroides species and an increased upregulation of the 
genes encoding the molecular products responsible for the creation of LPS when 
compared to their Russian counterparts. They also identified that these Bacteroides 
bacteria produce a distinct form of LPS, which is functionally and structurally different 
from the LPS produced by Escherichia coli more commonly found in the gut microbiota 
of Russian children. Importantly, this Bacteroides LPS variety attenuates the body’s 
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inflammatory response to endotoxemia clearly demonstrating that simple differences in 
the composition of microbiota between ethnic groups may ultimately predispose certain 
children to the development of inflammatory diseases such as asthma, lending to the 
higher prevalence of the disorder observed in non-Hispanic African Americans (Vatanen 
et al., 2016). 
 
Bile acids are also important gut microbiota metabolic byproducts. Bile acids diminish 
the manifestations of metabolic syndromes and enhance control of related inflammation 
in part by inhibiting NLRP3 inflammasome stimulation through G protein-coupled bile 
acid receptor 1 (TGR5) and protein kinase A (PKA) activation. Specific studies 
conducted examining this mechanism have shown that activation of the TGR5 receptor 
blocked inflammation stemming from both NLRP3 inflammasome activation and LPS-
dependent endotoxemia (Guo et al., 2016). This suggests that bile acids may be play a 
significant role in attenuating inflammation in the LONA obese asthma phenotype, their 
absence potentially resulting in increased disease severity. Finally, nitric oxide (NO) has 
been found to increase bile acid production via increased synthesis of hepatic molecular 
machinery responsible for bile acid creation, higher bacterial dehydroxylation in the 
colon, and increased hepatic conjugation (Sansbury et al., 2014, Comhair et al., 2015). 
Based on this, aerosolized NO may prove to be a possible therapeutic option for obese 






Unfortunately, convincing studies that have branded genetic vulnerability for 
development of asthma among the pediatric obese are few and far between, however, a 
common 16p11.2 inversion that may protect against predisposition to asthma and obesity 
has been identified in adolescents (Melén et al., 2013, González et al., 2014). This 
inversion seemingly upregulates expression of apolipoprotein B and SH2B1, both of 
which are obesity-associated proteins that inhibit type 1 IFN and IL-27. The investigators 
noted that this inversion may explain about 40% of the risk for combined susceptibilities 
to obesity and asthma. Other genes, including those that code for the β2-adrenergic 
receptor (ADRB2), TNF, and the lymphotoxin-α (LTA), have been associated with both 
pediatric obesity and asthma (Oguri et al., 2013, Aoki et al., 2006, Hamid et al., 2005). 
With a renewed focus on these particular genes, there may arise one that shows clear and 
true susceptibility for the combined disease pattern of obesity-related asthma.  
 
Epigenetics 
Disparities in the epigenetic environment have been found in the shared context of 
obesity and asthma (Almèn et al., 2012, Martínez et al., 2012, Stefanowicz et al., 2012, 
Kim et al., 2013). Differences in DNA methylation were determined at 5 loci on the FTO 
gene, variants of which are distinctly associated with pediatric obesity (Almén et al., 
2012). Likewise, in a genome-wide study, DNA hypomethylation at the IL-4 gene and 
the IFN-γ promoters were found in children with asthma (Kwon et al., 2008). These 
studies also located sites of differential methylation of several genes associated with 
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atopic and nonatopic inflammation among asthmatics, however, only 1 study found 
differences in DNA methylation among pediatric obesity-related asthma patients 
compared with counterparts with lean asthma and normal controls, who had neither 
condition (Stefanowicz et al., 2012, Rastogi et al., 2013). In the study conducted by 
Rastogi and others, very particular DNA methylation patterns were found to be strongly 
associated with pediatric obesity-related asthma, which included the hypomethylation of 
gene promoters for molecules involved in Th1 polarization such as chemokine ligand 5 
(CCL5) and IL-2 receptor α chain (IL2RA) and those that were hypermethylated such as 
the genes coding for immunoglobulin E and TGFB1 receptors, both of which are 
involved in Th1 cell inhibition. This is of extreme interest since Th2 biomarkers are 
markedly decreased in the airways in the LONA phenotype. Furthermore, the genes 
coding for PI3K and PPAR-γ, molecules that have important functions in glucose 
metabolism and lipid uptake in T cells, were hypomethylated in obesity-related 
asthmatics as compared to that found in healthy controls, suggesting that more molecules 
associated with both inflammation and metabolic dysregulation may be differentially 
methylated in obese asthmatics (MacIver et al., 2013, Szarc vel Szic et al., 2010). 
Although, these relatively new investigations put forward novel discoveries, they are only 
topical, preliminary analyses which clearly present a need for in-depth studies that more 
conclusively determine the effect of diet modification on DNA methylation and this 
cause-effect relationship that underlies dyslipidemia, insulin resistance, and systemic 
inflammation specifically in obese asthmatics which could potentially lead the way to 
more advanced, targeted, and efficacious treatments.  
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MANAGEMENT AND TREATMENT 
 
Treatment modalities for obese asthmatics, as reviewed in the literature, seem to favor 
remedying the adiposity component before attempting to attenuate asthma symptoms, 
which is primarily done through controller medications, as obesity and its associated 
physiological changes cause poor response to standard pharmacotherapeutic treatments 
for asthma. Thus, the forthcoming summary for management and treatment of pediatric 
obesity-related asthma revolves mostly around diminishing the effects of obesity as there 
exists well-studied and conclusive approaches for this disorder.  
 
Lifestyle Interventions  
For most, if not all, overweight and obese asthmatics, the most utilized and effective 
lifestyle interventions, particularly as the first line of defense, include dietary, physical 
activity and behavioral therapy. Dietary therapy typically involves creating an energy 
deficit most appropriately done by reducing caloric intake, which can be achieved 
through a thorough education on how to best modify the diet to properly meet this goal. 
Increasing physical activity will also greatly assist in producing this energy deficit by 
directly elevating energy expenditure and improving body composition through a 
reduction in body fat and a prevention of the decrease in muscle mass, which is typically 
observed during weight loss. Additionally, potential benefits include improved 
cardiovascular fitness. Behavioral therapy, which includes development of self-
monitoring strategies, should be utilized as a means to increase fulfillment of any 
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arranged dietary and activity-related adjustments (NHLBI Obesity Education Initiative 
2000). Many studies have postulated that diet alterations and improvements can 
ameliorate or abolish the clinical presentations and symptoms of asthma, however, few 
randomized controlled trials (RCT) have been carried out to date. One of these RCTs 
utilized a 14-week dietary restriction program, which resulted in a weight loss of 15% 
and increases in FEV1 and FVC in the experimental group (Stenius-Aarniala et al., 
2000). Interestingly, participants in the experimental group had considerably mitigated 
dyspnea, fewer asthma exacerbations, and reduced asthma quick reliever usage as 
compared with the control group (Stenius-Aarniala et al., 2000). Utilizing a 12-month 
behavioral intervention, which involved every type of lifestyle modification including 
diet adjustment, increased cardiovascular exercise, and teaching of self-management and 
relevant self-sufficiency skills, a more recent study conducted with 330 obese adolescents 
with uncontrolled asthma achieved a higher weight loss in the experimental group 
compared to the control. Although this small difference in weight loss did not result in a 
statistically significant difference in lung function, asthma control, or asthma 
exacerbation rates, the participants with equal to or greater than 5% weight loss did 
however achieve higher scores on their asthma control questionnaire (ACQ) as compared 
to the obese asthmatic adolescents that only lost equal to or less than 3% of their initial 
body weight. Another RCT instead utilized a 10-week weight loss intervention in obese 
asthmatic adolescents to compare the different results of exercise intervention, dietary 
intervention, and a combination of both (Scott et al., 2013). The two groups that utilized 
the dietary intervention achieved a significant amount of weight loss over 10 weeks, and, 
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remarkably, for all groups improvements in quality of life were demonstrated. Notably, in 
the diet and combined groups only, asthma control improved and plasma leptin decreased 
(Scott et al., 2013). Seemingly, the most meaningful result was that, in the majority of 
patients, weight loss of only 5–10% resulted in a substantial enhancement in asthma 
control and asthma-related quality of life. This clearly suggests that even small weight 
losses should be emphasized and pushed for as part of the management plan specifically 
in regards to this population (Scott et al., 2013). Although the data from the RCT 
conducted thus far is limited and the conclusions ambivalent, there still is plenty of 
meaningful evidence collected from non-randomized trials that clearly demonstrates the 
effectiveness of these lifestyle interventions in diminishing the clinical manifestations 
and outcomes of asthma in the obese such as dyspnea, asthma control, FEV1, FVC, and 
quality of life (Aaron et al., 2004, Hakala et al., 2000, Johnson et al., 2007). 
 
Pharmacotherapy  
When lifestyle interventions have not achieved weight loss after 6 months or an asthmatic 
has a BMI equal to or greater then 30kg/m2, a threshold usually used as defining obesity, 
or a BMI equal to or greater then 27kg/m2 if concurrent obesity-related comorbidities are 
present, pharmacotherapy is recommended (NHLBI Obesity Education Initiative 2000). 
The literature seems to suggest that pharmacotherapies should only be used in 
conjunction with a management program that includes elements of lifestyle interventions 
as detailed in order to maximize potential benefit in the face of refractory, disease-related 
developments. The combined therapy regimen of sibutramine and orlistat has been 
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approved for long-term use in weight loss in adolescent asthmatics, however, each drug 
conveys its own unique adverse effects that must be adequately and appropriately 
mitigated. Orlistat is a pancreatic enzyme inhibitor that inhibits fat absorption from the 
intestine whose side effects include the reduction of the absorption of nutritionally 
necessary fat-soluble vitamins and nutrients. Sibutramine is a serotonin-reuptake inhibitor 
that suppresses appetite whose side effects include increased blood pressure and 
tachycardia. In a RCT with 33 severe asthmatics with obesity ages 12 years of age and 
older conducted by Dias-Junior et al., whose goal was to determine the efficacy of this 
combined pharmacotherapy modality, the experimental group used dietary intervention 
techniques in combination with sibutramine and orlistat for 6 months. These experimental 
group members lost on average 7.5% of their initial body weight, their ACQ and FVC 
measures increased, symptoms diminished, and asthma reliever or rescues therapy use 
decreased (Dias-Junior et al., 2014).  
 
There is a great deal of evidence that demonstrates that obese children with asthma do not 
respond well to controller therapy typically prescribed for the condition in the younger 
pediatric population (Forno et al., 2011, Sutherland et al., 2010, Camargo et al., 2010). 
These standard controllers include dexamethasone and montelukast, which has been 
reported to be inferior in treatment of asthma in obese children to inhaled corticosteroids 
and combination inhaled corticosteroid-long acting β agonists (LABA) (Camargo et al., 
2010, Sutherland et al., 2010, Peters et al., 2006). It is important to note that response to 
rescue therapy, typically a short-acting β agonist (SABA), in obese children is usually not 
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different in comparison to their non-obese counterparts, whereas the response to 
controller therapy is (Yeh et al., 2011). One study showed that upon dexamethasone 
treatment of mononuclear cells, which are usually immune cells, isolated from obese 
patients, there was a downregulation of intracellular MKP1, a signaling molecule 
involved in steroid responses. This clearly demonstrated that there indeed are altered 
immune responses to steroids at the cellular level in the obese (Stream et al., 2012, 
Sutherland et al., 2008). Current therapies for asthma were developed to target allergic 
asthma in lean individuals, not the obese because almost all approved asthma 
pharmacotherapies were first created and tested using lean animal models of asthma, and 
even tested in patients that are far leaner than the typical patient population observed 
today. Thus, for now, treatment modalities aimed at controlling asthma in the obese are 
unfortunately similar as used in lean asthmatics and nonspecific, resulting in poor clinical 
asthma management, however, this unquestionably has called for the development of 
asthma medications specifically for obese patients. 
 
Weight Loss Surgery 
Bariatric surgery involves the creation of a physical barrier around and on the stomach 
that diminishes space in the organ to store food thereby reducing energy intake and thus 
creating that sought-after energy deficit. This intervention is the most effectual treatment 
for attaining large weight changes. However, this surgery is only a procedure suitable for 
patients with extreme obesity, defined as BMI equal to or greater then 40kg/m2, or 
patients with BMI equal to or greater then 35kg/m2 and serious obesity-related 
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comorbidities. The risks associated with bariatric surgery are significant, therefore, it 
should only be recommended when other interventions, such as diet and exercise and 
even pharmacotherapy, have proven unsuccessful and the patient clearly has a refractory 
condition and possesses a very high risk for obesity-associated mortality (NHLBI Obesity 
Education Initiative 2000). Numerous studies have reported that following bariatric 
surgery there are clear improvements in asthma outcomes, including enhanced lung 
function, quality of life, AHR, and reduced controller and reliever use (Macgregor et al., 
1993, Maniscalco et al., 2008, Dixon et al., 2011, Sideleva et al., 2012). While these 
clinical improvements were observed, few studies have demonstrated any decrease in 
airway inflammation in response to the surgical procedure. The study carried out by 
Dixon and associates, determined that 12 months after bariatric surgery, there were no 
changes in the neutrophil and eosinophil content of the extracted bronchoalveolar lavage 
(BAL), however, in the BAL and serum, adiponectin concentrations were increased and 
biomarkers indicative of an increase in the immune cells in peripheral circulation were 
present, suggestive that some systemic inflammation had persisted, but had not infiltrated 











Pediatric obesity-related asthma is an established public health problem with clear indices 
of its economic, societal, and personal burdens. Obesity affects the clinical manifestations 
of asthma in a variety of ways. Seemingly, it seems that obesity modulates and worsens a 
pre-existing allergic disease that developed early in life, in line with what has been 
described as the EOA obese asthma phenotype, whereas, in the cases suggestive of the 
LONA phenotype, inflammation mediated by obesity and the mechanically hindering 
effects of a large trunk reduce lung volumes, among other obesity-related effects, 
seemingly pointing to a late-onset asthma pathogenesis, characterized by increased AHR. 
The complicating metabolic activity of excess adipose tissue coupled with its conferment 
of immune dysregulation clearly negatively affect, even worsen, the functionality of the 
airways in the context of asthma. Although, there is growing data that suggests distinct 
recognition of two phenotypes for this disorder, LONA and EOA obese asthma, the 
evidence available now in this regard is limited and the literature indicates that the 
similarities and commonalities far outweigh the differences, therefore, it is in the best 
interest of the scientific community to focus on the disease in a more general, all-
encompassing manner. There evidently are few effective treatments and management 
approaches for this disease, most likely stemming from an incomplete understanding in 
the clinical and biomedical communities of the mechanisms that underlie this association. 
Research is necessary to better define the mechanisms responsible for this distinct disease 
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